LAUSR

Introduction/Background Persistent infection with 1 of 14 high-risk genotypes Human Papilloma Virus (HPV) genotypes is the crucitial for the development of cervical cancer. high grade cervical cancer precursors. These HPV genotypes can be named as high risk HPV types (HR-HPV). The reassuring management of women with cytology negative, HR-HPV positive is important especially after the widespread use of HPV testing either as a cotest or primary screening. The aim of our study was to compare the colposcopic biopsy results of women with HPV 16/18 with other HR-HPV genotypes and determine positive predictive values (PPV) for CIN2+ of other HR HPV genotypes. Methodology We prospectively had included the women with negative cytology and positive HR-HPV test other than HPV 16/18. Control group was composed of women with negative cytology positive test result for either HPV 16 or HPV 18. Women with HR-HPV positive, cytology negative referred to immediate colposcopy. Results Totaly 185 colposcopies were performed for HRHPV test positive, of these 97 had HRHPV positive test other than HPV 16/18. The prevalance of CIN1 and CIN2 is significantly higher in HPV16/18 group than pooled other HRHPV group ( 34.1% vs 17.5%, p=0.01 for CIN 1+; 14.8% vs 5.2%, p=0.03 for CIN 2+). The prevalance of CIN3 was almost three fold in women with HPV 16/18 (9.1% vs 3.1%). PPV for CIN 2+ was 16.4 (9.1–27.3) for HPV16, 11.7 (2–37.7) for HPV18, 20 (3.5–55.7) for HPV 31, 11.1 (0.6–49.3) for HPV 51, 12.5 (0.6–53.3) for HPV 58 and 59. Conclusion Although HPV 16 preserve high PPV among basal cytology negative population, especially HPV 33, 51, 58, 59 and 18 had similiar predictive values. Full genotyping or genotyping of HR-HPV could help reassuring traiage of women with negative cytology. Disclosure Nothing to disclose. Abstract P11 Table 1 Immediate colposcopic biopsy diagnosis among HPV16/18 and O-HRHPV groups. HPV16/18 includes any type of infection with HPV16+ or HPV18+; OHRH HPV 16–18 (n=88) O-HRHPV (n=97) p value CIN 1+ (n,%) 30 (34.1) 17 (17.5) 0.01 CIN 2+ (n,%) 13 (14.8) 5 (5.2) 0.03 CIN 3 (n,%) 8 (9.1) 3 (3.1) 0.08 Abstract P11 Table 2 Diagnostic value of HRHPV for screening high level cervical lesions in cytology negative population CIN 2+ PPV ( 95% CI) CIN 3 PPV ( 95% CI) HPV 16/18 14.7 (8.4–24.3) 9.1 (4.2–17.6) HPV 16 16.4 (9.1–27.3) 10.1 (5.1–20.9) HPV 18 11.7 (2–37.7) - O-HRHPV 5.1 (1.9–12.1) 3.1 (0.8–9) HRHPV 9.7 (6–15) 5.9 (3.1–10.6) HPV 31 20 (3.5–55.7 ) - HPV 51 11.1 (0.6–49.3) 11.1 (0.6–49.3) HPV 58 12.5 (0.6–53.3) - HPV 59 12.5 (0.6–53.3) 12.5 (0.6–53.3)